Q-omics provides the consensus-scored RAPGEF3 profile across patient tissues and cancer cell-line models. RAPGEF3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RAPGEF3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RAPGEF3 RNA expression shows 23,638 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KIRC, and GBM as cancer lineages where RAPGEF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAPGEF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAPGEF3 survival associations across molecular data types. RAPGEF3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAPGEF3 RNA expression–survival associations across cancer types. High RAPGEF3 expression shows unfavorable associations in OV and LUSC, but favorable associations in UVM, MESO, LIHC and THYM. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RAPGEF3 RNA expression.
This table summarizes RAPGEF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAPGEF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAPGEF3 shows lower tumor expression in KIRC, KIRP, LUAD, LUSC and BLCA and higher tumor expression in LIHC. The KIRC box plot shows higher RAPGEF3 RNA expression in normal versus tumor tissue (log2 FC = −2.328, t-test p < 0.001).
This table shows molecular features associated with RAPGEF3 in patient tissues and cancer cell lines. In patient samples, RAPGEF3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAPGEF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
